Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:AUP NASDAQ:CARA CVE:NOT NASDAQ:TLRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPAurinia PharmaceuticalsC$0.00C$11.77▼C$26.00C$2.15BN/A229,895 shs4.61 million shsCARACara Therapeutics$15.19$8.13▼$19.08$24.33M0.4122,224 shs237,144 shsNOTNoront ResourcesC$1.10-0.5%C$1.09C$0.23▼C$1.11C$612.18MN/A512,544 shs68,388 shsTLRYTilray Brands$1.12+5.7%$0.91$0.35▼$1.88$1.17B2.0360.94 million shs46.52 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPAurinia Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CARACara Therapeutics0.00%0.00%0.00%0.00%+51.05%NOTNoront Resources0.00%0.00%0.00%0.00%0.00%TLRYTilray Brands0.00%-5.88%-5.08%+177.23%-34.88%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPAurinia PharmaceuticalsC$0.00C$11.77▼C$26.00C$2.15BN/A229,895 shs4.61 million shsCARACara Therapeutics$15.19$8.13▼$19.08$24.33M0.4122,224 shs237,144 shsNOTNoront ResourcesC$1.10-0.5%C$1.09C$0.23▼C$1.11C$612.18MN/A512,544 shs68,388 shsTLRYTilray Brands$1.12+5.7%$0.91$0.35▼$1.88$1.17B2.0360.94 million shs46.52 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPAurinia Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CARACara Therapeutics0.00%0.00%0.00%0.00%+51.05%NOTNoront Resources0.00%0.00%0.00%0.00%0.00%TLRYTilray Brands0.00%-5.88%-5.08%+177.23%-34.88%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPAurinia Pharmaceuticals 0.00N/AN/AN/ACARACara Therapeutics 0.00N/AN/AN/ANOTNoront Resources 0.00N/AN/AN/ATLRYTilray Brands 2.33Hold$1.9472.99% UpsideCurrent Analyst Ratings BreakdownLatest NOT, AUP, TLRY, and CARA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025TLRYTilray BrandsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$1.50 ➝ $2.007/29/2025TLRYTilray BrandsZelman & AssociatesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPAurinia PharmaceuticalsC$57.59M0.00N/A6.75C$2.59 per share0.00CARACara Therapeutics$7.14M0.00N/AN/A$12.58 per share0.00NOTNoront ResourcesN/AN/AC$0.01 per share84.23C($0.03) per shareN/ATLRYTilray Brands$210.48M5.86$0.15 per share7.33$1.40 per share0.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPAurinia PharmaceuticalsN/A-C$1.48N/AN/AN/AN/AN/AN/AN/ACARACara Therapeutics-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/ANOTNoront ResourcesN/A-C$0.15N/A∞N/AN/AN/AN/AN/ATLRYTilray Brands-$2.19B-$2.31N/AN/AN/A-265.69%-6.83%-5.45%10/9/2025 (Estimated)Latest NOT, AUP, TLRY, and CARA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/9/2025Q1 2026TLRYTilray Brands-$0.03N/AN/AN/A$205.75 millionN/A7/28/2025Q4 2025TLRYTilray Brands-$0.03$0.02+$0.05-$1.30$250.41 million$224.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUPAurinia PharmaceuticalsN/AN/AN/AN/AN/ACARACara TherapeuticsN/AN/AN/AN/AN/ANOTNoront ResourcesN/AN/AN/AN/AN/ATLRYTilray BrandsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPAurinia Pharmaceuticals2.6911.9311.02CARACara TherapeuticsN/A4.774.71NOTNoront ResourcesN/A0.160.15TLRYTilray Brands0.202.461.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPAurinia PharmaceuticalsN/ACARACara Therapeutics44.66%NOTNoront ResourcesN/ATLRYTilray Brands9.35%Insider OwnershipCompanyInsider OwnershipAUPAurinia PharmaceuticalsN/ACARACara Therapeutics3.10%NOTNoront ResourcesN/ATLRYTilray Brands0.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPAurinia Pharmaceuticals300128.40 millionN/ANot OptionableCARACara Therapeutics804.57 million4.43 millionOptionableNOTNoront Resources101,700559.07 millionN/ANot OptionableTLRYTilray Brands2,8421.10 billion1.09 billionOptionableNOT, AUP, TLRY, and CARA HeadlinesRecent News About These CompaniesCannabis Stocks To Research - September 13th5 hours ago | marketbeat.comPromising Cannabis Stocks To Consider - September 12thSeptember 13 at 1:01 PM | marketbeat.comTilray Brands (NASDAQ:TLRY) Shares Gap Up - Should You Buy?September 13 at 10:36 AM | marketbeat.comCannabis Stocks Worth Watching - September 11thSeptember 12 at 1:40 PM | marketbeat.comTilray Brands (NASDAQ:TLRY) Shares Gap Down - Here's What HappenedSeptember 12 at 12:37 PM | marketbeat.comTilray Brands (NASDAQ:TLRY) Trading Down 3.9% - Should You Sell?September 11 at 3:33 PM | marketbeat.comPromising Cannabis Stocks To Follow Today - September 10thSeptember 11 at 1:35 PM | marketbeat.comPot Stocks Rallied Hard in August: Is There More to Come?September 10, 2025 | msn.comTilray Brands (NASDAQ:TLRY) Trading Up 1.3% - Here's WhySeptember 10, 2025 | marketbeat.comTop Cannabis Stocks To Consider - September 9thSeptember 10, 2025 | marketbeat.comTilray Brands (NASDAQ:TLRY) Shares Down 6.3% - What's Next?September 9, 2025 | marketbeat.comBreckenridge Brewery Awarded Silver Certification by the Colorado Green Business Network for Excellence in Sustainability PracticesSeptember 9, 2025 | globenewswire.comShort Interest in Tilray Brands, Inc. (NASDAQ:TLRY) Drops By 20.0%September 9, 2025 | marketbeat.comTilray Brands, Inc. (TLRY) Stock Falls Amid Market Uptick: What Investors Need to KnowSeptember 8, 2025 | zacks.comTilray Brands (NASDAQ:TLRY) Trading Up 2.2% - Here's What HappenedSeptember 6, 2025 | marketbeat.comCannabis Stocks To Add to Your Watchlist - September 5thSeptember 6, 2025 | marketbeat.comTilray Brands (NASDAQ:TLRY) Shares Down 4.2% - Should You Sell?September 5, 2025 | marketbeat.comTop Cannabis Stocks To Follow Now - September 4thSeptember 5, 2025 | marketbeat.comTilray Brands (NASDAQ:TLRY) Stock Price Down 5.2% - Here's WhySeptember 4, 2025 | marketbeat.comBreckenridge Distillery and Denver Broncos Kick Off Fifth Year of Partnership with New Lineup of Spirits, Including Limited-Edition Broncos Honey WhiskeySeptember 4, 2025 | globenewswire.comTilray Brands (TLRY) Surges on Cannabis Sector Buzz as Profits Go Up in SmokeSeptember 3, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMongoDB Roars Back to Life: It’s Not Too Late to Buy MoreBy Thomas Hughes | August 27, 2025Buy, Sell, or Hold? Insiders Pile Into These 3 Healthcare StocksBy Thomas Hughes | August 19, 2025Super Micro Computer Stock Hasn't Priced in Growth YetBy Gabriel Osorio-Mazilli | August 25, 2025Hyperscaler Spending Could Supercharge Super Micro Computer StockBy Gabriel Osorio-Mazilli | August 19, 2025Buffett’s Cash Hoard Signals Market Caution, Value Plays EmergeBy Gabriel Osorio-Mazilli | August 19, 2025NOT, AUP, TLRY, and CARA Company DescriptionsAurinia Pharmaceuticals TSE:AUPAurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.Cara Therapeutics NASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Noront Resources CVE:NOTC$1.10 -0.01 (-0.45%) As of 04/6/2022Noront Resources Ltd., a resource company, engages in the acquisition, development, and exploration of base and precious metals in Canada. It explores for nickel, copper, zinc, platinum group metals, chromite, iron, titanium, vanadium, gold, and silver. The company's flagship property is the Eagle's Nest project located in the James Bay Lowlands, Ontario. The company was formerly known as White Wing Resources Inc. and changed its name to Noront Resources Ltd. in July 1983. Noront Resources Ltd. was incorporated in 1980 and is headquartered in Toronto, Canada.Tilray Brands NASDAQ:TLRY$1.12 +0.06 (+5.66%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.12 +0.00 (+0.45%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
